Forty-six allogeneic hematopoietic stem cell transplantation (HSCT) patients were monitored for the presence of CMV antibodies, CMV-DNA and CMV antigens after transplantation. Immunoenzymatic serological tests were used to detect IgM and the increase in CMV IgG antibodies (increase IgG), a nested polymerase chain reaction (N-PCR) was used to detect CMV-DNA, and an antigenemia assay (AGM) was us...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with CCR5– donor cells is the only treatment known to cure HIV-1 in patients underlying malignancy. This likely due a cell–mediated graft-versus-host effect targeting HIV reservoirs. Allo-HSCT would not be an acceptable therapy for most people living transplant-related side effects. Chimeric antigen receptor (CAR) immunotherapies sp...

Hematopoietic stem cell transplantation (HSCT) applied to children is associated with high risk for organ failure, ICU admission, morbidity and mortality. "Respiratory failure" after HSCT carries a historically grave prognosis. Factors associated with high risk for critical care complications in HSCT patients have been identified, but are dependent on timing and intensity of interventions. Seve...

Non-Hodgkin's lymphoma (NHL) includes a diverse set of conditions ranging from high-grade aggressive to more indolent low-grade disease. Hematopoietic stem cell transplantation (HSCT) has a valuable role in the management of these conditions and can provide long-term remission in selected cases. This article presents the current use of allogeneic and autologous HSCT in a number of subtypes of NHL.

GlobalUseof Peripheral BloodvsBoneMarrow as Sourceof StemCells forAllogeneic Transplantation inPatientsWithBoneMarrowFailure Hematopoietic stemcell transplantation (HSCT) is a therapeutic option formany patients with bonemarrow failure.1 Bone marrowwas initially the only stem cell source available until the 1990swhen peripheral blood stem cells (PBSCs) and cord blood began to be used. Currently...

The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated attack of recipient tissue by donor T cells contained in the transplant. Mouse models of GvHD have provided important insights into the pathophysiology of this disease, which have helped to improve the success rate of...

Allogeneic hematopoietic stem cell transplantation (HSCT) corrects the Wiskott-Aldrich syndrome (WAS) phenotype. However, the toxicity and mortality frequently associated with this approach warrant the exploration of new therapeutic strategies. Transplantation studies of a murine model of WAS deficiency have been limited by the occurrence of a radiation-induced fatal exacerbation of a pre-exist...

Factors associated with spermatogenesis after allogeneic hematopoietic stem cell transplantation (HSCT) were assessed in this prospective, single-center, cross-sectional study. All consecutive men aged 18 years or older and in complete remission 2 years or longer after HSCT were invited to participate. Seminal fluid analysis was performed on freshly collected samples according to World Health O...

Background: Leukemia and hematopoietic stem cell transplantation (HSCT) create physical, psychological, social, and spiritual distresses in patients. Understanding this threatening situation in adults with leukemia undergoing HSCT will assist health care professionals in providing holistic care to the patients. Objectives: The aim of the present study was exploring the perceived threat in adult...

BACKGROUND Matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and efficacy of HSCT from unrelated donors is less certain. OBJECTIVE We evaluated the outcomes and overall survival in patients with CGD after HSCT. METHODS We report the outcomes for 11 children undergoing HSCT from an MRD ...